Treatment of immunocompromised patients with suspected invasive fungal infections: economic analysis of diagnostic-driven versus empirical strategies in Algeria and Egypt

References

• Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100(13):4358–4366.
   PubMed Web of Science ®Google Scholar
• Ananda-Rajah MR, Cheng A, Morrissey CO, et al. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach. Antimicrob Agents Chemother. 2011;55(5):1953–1960.
   PubMed Web of Science ®Google Scholar
• Ceesay MM, Desai SR, Berry L, et al. A comprehensive diagnostic approach using galactomannan, targeted β-D-glucan, baseline computerized tomography and biopsy yields a significant burden of invasive fungal disease in at risk haematology patients. Br J Haematol. 2015;168(2):219–229.
   PubMed Web of Science ®Google Scholar
• Girmenia C, Raiola AM, Piciocchi A, et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant. 2014;20(6):872–880.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis. 2010;50(8):1091–1100.
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study—Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis. 2007;45(9):1161–1170.
   PubMed Web of Science ®Google Scholar
• Corzo-León DE, Satlin MJ, Soave R, et al. Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens. Mycoses. 2015;58(6):325–336.
   PubMed Web of Science ®Google Scholar
• Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48(3):265–273.
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Chatterjee SS, Das A, et al. Invasive aspergillosis in developing countries. Med Mycol. 2011;49(Suppl. 1):S35–S47.
   PubMedGoogle Scholar
• Hadrich I, Makni F, Sellami H, et al. Invasive aspergillosis: epidemiology and environmental study in haematology patients (Sfax, Tunisia). Mycoses. 2010;53(5):443–447.
   PubMed Web of Science ®Google Scholar
• Bassiri JS, Khaksar AA. Deep-seated fungal infections in immunocompromised patients in Iran. Iran J Allergy Asthma Immunol. 2005;4(1):27–32.
   PubMedGoogle Scholar
• Cornely OA, Böhme A, Buchheidt D, et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica. 2009;94(1):113–122.
   PubMed Web of Science ®Google Scholar
• Al-Abdely HM, Alothman AF, Salman JA, et al. Clinical practice guidelines for the treatment of invasive Aspergillus infections in adults in the Middle East region: expert panel recommendations. J Infect Public Health. 2014;7(1):20–31.
   PubMed Web of Science ®Google Scholar
• Alothman AF, Al-Musawi T, Al-Abdely HM, et al. Clinical practice guidelines for the management of invasive Candida infections in adults in the Middle East region: expert panel recommendations. J Infect Public Health. 2014;7(1):6–19.
   PubMed Web of Science ®Google Scholar
• Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005;41(9):1242–1250.
   PubMed Web of Science ®Google Scholar
• Mao N, Lesher B, Liu Q, et al. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in China. Clinicoecon Outcomes Res. 2016;8:275–285.
   PubMed Web of Science ®Google Scholar
• Barnes R, Earnshaw S, Herbrecht R, et al. Economic comparison of an empirical versus diagnostic-driven strategy for treating invasive fungal disease in immunocompromised patients. Clin Ther. 2015;37(6):1317–1328.
   PubMed Web of Science ®Google Scholar
• de Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–1821.
   PubMed Web of Science ®Google Scholar
• Marchetti O, Lamoth F, Mikulska M, et al. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant. 2012;47(6):846–854.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis. 2009;48(8):1042–1051.
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Nosari A, et al. The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. Haematologica. 2011;96(9):1366–1370.
   PubMed Web of Science ®Google Scholar
• Hahn-Ast C, Glasmacher A, Mückter S, et al. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother. 2010;65(4):761–768.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Hathorn JW, Schuster MG, et al. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med. 2000;108(4):282–289.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408–415.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289–1297.
   PubMed Web of Science ®Google Scholar
• Viscoli C, Herbrecht R, Akan H, et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother. 2009;64(6):1274–1281.
   PubMed Web of Science ®Google Scholar
• Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA. 1997;277(4):307–311.
   PubMed Web of Science ®Google Scholar
• Martín-Peña A, Gil-Navarro MV, Aguilar-Guisado M, et al. Cost-effectiveness analysis comparing two approaches for empirical antifungal therapy in hematological patients with persistent febrile neutropenia. Antimicrob Agents Chemother. 2013;57(10):4664–4672.
   PubMed Web of Science ®Google Scholar